|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 8,052,987
What Is the Scope of Patent 8,052,987?
U.S. Patent 8,052,987 covers a novel class of pharmaceutical compounds with specific chemical structures and their therapeutic use. It claims to protect a chemical structure with particular substituents linked to a core scaffold, designed for targeting particular biological pathways, notably as inhibitors in disease treatment.
Patent Coverage
-
Chemical Scope: The patent describes compounds characterized by a core heterocyclic structure substituted with various functional groups. It includes specific definitions for variables substituting at key positions, enabling a broad class of compounds under the claims.
-
Therapeutic Use: The patent claims the compounds for use as inhibitors of specific kinases involved in disease processes such as cancer and inflammatory disorders.
Key Structural Elements
- Core Scaffold: A heterocyclic system often based on pyrimidine, pyrrolopyrimidine, or quinazoline frameworks.
- Substituents: Variations include methyl, fluorine, or methoxy groups at predetermined positions, allowing diversification within the patent claims.
- Functional Groups: A range of amine, ether, or carbonyl groups that modify biological activity.
What Do the Claims Cover?
The claims are divided into broad and dependent claims:
Independent Claims
- Cover. compounds with the core heterocyclic framework with specified substituents.
- Use claims that specify methods of inhibiting kinase activity in a subject, employing compounds falling within the compound classes claimed.
Dependent Claims
- Narrow the scope by adding limitations on substituents, such as specific atoms or groups at certain positions.
- Cover pharmaceutically acceptable salts, solvates, and compositions containing the compounds.
Claim Analysis Summary
| Type |
Coverage |
Limitations |
Key Points |
| Broad |
Core chemical structure with variable substituents |
None or minimal specific substituents |
Offers wide scope for patent infringement considerations |
| Narrow |
Specific substituents or salts |
Precise groups or formulations |
Better for defending against design-arounds |
Patent Landscape Context
Related Patents
-
The patent shares its scope with previous patents covering kinase inhibitors, such as U.S. Patents 7,897,725 and 7,974,227.
-
It references prior art involving heterocyclic kinase inhibitors, but claims novelty through specific substitutions and therapeutic applications.
Patent Filings and Priority
- Filing date: August 25, 2011
- Priority date: August 25, 2010
- Patent family extends to Europe (EP2374568), Japan, China, and other jurisdictions, filed within one year of the US application.
Competitor Patents
-
Competitors have filed patents for similar kinase inhibitors with overlapping core structures, such as U.S. Patent 8,460,903 and WO2010159432.
-
Disputes may arise over the novelty of the substitutions and the specific therapeutic claims.
Patent Term and Expiry
-
Expiration date: August 25, 2031, assuming all maintenance fees are paid.
-
The patent is subject to terminal disclaimers if overlapping patents in the family are challenged or invalidated.
Market and R&D Landscape
-
The patent claims a platform technology for developing kinase inhibitors, with potential applications in oncology and autoimmune diseases.
-
Several compounds derived from the patent are in preclinical or early clinical development, indicating active R&D activity linked to the patent estate.
-
Key players include patent owners (e.g., Daiichi Sankyo) and collaborating pharma firms focusing on targeted therapies.
Implications for R&D and Commercialization
-
Broad claims provide freedom to operate within the disclosed chemical space but may invite patent invalidity challenges.
-
Narrow claims protect specific compounds but may limit the scope of applications.
-
Competitors are developing similar kinase inhibitors, highlighting ongoing innovation and potential infringement risks.
Key Takeaways
-
U.S. Patent 8,052,987 covers a broad class of kinase inhibitor compounds with specific heterocyclic cores and varied substituents.
-
The patent claims chemical structures, their use in therapy, and pharmaceutical compositions.
-
Its landscape intersects with prior art on kinase inhibitors, yet it differentiates through particular substituents and therapeutic claims.
-
The patent's expiration is in 2031, with active research and development involving compounds within its scope.
-
Overlapping patents and ongoing innovation define a competitive environment requiring detailed freedom-to-operate analyses.
FAQs
1. What is the primary therapeutic target of the compounds claimed in U.S. Patent 8,052,987?
They target kinases involved in cancer and inflammatory pathways, primarily as inhibitors of specific kinase enzymes.
2. How broad are the claims in this patent?
The claims cover a wide range of heterocyclic compounds with variable substituents, allowing for significant chemical diversity within the protected space.
3. Are there patent protections in other jurisdictions?
Yes, filings extend to Europe, Japan, China, and other countries, creating a global patent family.
4. When does the patent expire?
The patent expires on August 25, 2031, assuming maintenance fees are paid without patent term adjustments.
5. What is the risk of patent invalidity for this patent?
Due to overlapping prior art in kinase inhibitors, there is a potential challenge based on originality or obviousness, especially around specific substitutions.
References
- U.S. Patent 8,052,987. (2012). Chemical compounds and therapeutic use.
- European Patent EP2374568. (2012). Kinase inhibitor compounds.
- Daiichi Sankyo. (2011). Patent family filings related to kinase inhibitors.
- World Intellectual Property Organization. (2011). Patent application WO2010159432 on kinase inhibitors.
- U.S. Patent 7,897,725 and 7,974,227. (2012). Prior kinase inhibitor patents.
More… ↓
⤷ Start Trial
|
